Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AK1940 in Healthy Japanese and Caucasian Subjects
jRCT2071250141Phase 1Recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gumokimab (4 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Pharmacokinetic parameters and Safety endpoints. Started Apr 2026; status: recruiting.
02
Drugs
gumokimab
Beyond the preview
Go deeper on jRCT2071250141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250141.